Disability

IRLAB Receives Milestone Payment of USD 2.5 million in Conjunction with First Dosing in a Phase I Study with IRL757 in Healthy Older Adults

GOTHENBURG, SWEDEN / ACCESSWIRE / October 8, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company…

1 month ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of…

2 months ago

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines

New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute…

2 months ago

Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone…

2 months ago

Shearwater Health Partners with Laguna Health, Leveraging Cutting-Edge AI Solutions

The partnership enables Shearwater to integrate advanced conversational AI and real-time insights into its Clinical Process Outsourcing operations  NASHVILLE, Tenn.,…

2 months ago

AudioEye Achieves HIPAA Compliance and SOC 2 Type II Certification, Strengthening Data Protection and Security Measures for Its Customers

New compliance and certification measures unlock opportunities in healthcare and enterprise TUCSON, Ariz., Sept. 26, 2024 /PRNewswire/ -- AudioEye, Inc. (Nasdaq:…

2 months ago

Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

2 months ago

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira…

2 months ago

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025GAITHERSBURG, Md., Sept. 25, 2024…

2 months ago